drugset / Trial / NCT04604795

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole

NCT04604795

Phase 1 Completed 65 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This is a 3-part first time into human study (FTIH) study for GSK3915393. Parts A and B of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending and repeat oral doses of GSK3915393 in healthy adult participants. Part C will evaluate the impact of co-administration of GSK3915393 with grapefruit juice and itraconazole on the PK of GSK3915393.

Timeline

Start
2020-11-04
Primary completion
2021-06-29
Completion
2021-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK3915393 Unknown Oral
Subject Itraconazole Small molecule Oral

Indications